STOCK TITAN
  1. Home
  2. Sec-filings
  3. OSTX
  4. [D] OS Therapies Incorporated SEC Filing

[D] OS Therapies Incorporated SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
D
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock OSTX logo
OS THERAPIES INCORPORATED

NYSE:OSTX

OSTX Rankings

#8167 Ranked by Market Cap
N/A Ranked by Dividends

OSTX Latest News

Jul 14, 2025
OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer
Jul 10, 2025
OS Therapies Provides Clinical & Global Regulatory Updates
Jul 3, 2025
OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Jun 30, 2025
OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference
Jun 24, 2025
OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

OSTX Latest SEC Filings

Jul 14, 2025
[8-K] OS Therapies Incorporated Reports Material Event
Jun 27, 2025
[8-K] OS Therapies Incorporated Reports Material Event
Jun 24, 2025
[8-K] OS Therapies Incorporated Reports Material Event

OSTX Stock Data

50.47M
18.72M
34.84%
0.67%
2.97%
Biotechnology
Pharmaceutical Preparations
Link
United States
ROCKVILLE